To explore the clinical value of butylphthalide combined with idebenone in the treatment of elderly patients with vascular dementia.

The retrospective analysis selected 165 elderly patients with vascular dementia admitted to Hebi Chaoyang Ren'ai Hospital from January 2020 to June 2021 as the research objects. After analyzing the patients' medical records, all patients were divided into a control group (82 cases) and a study group (83 cases) according to different medication regimens. There were 42 males and 40 females in the control group, aged (69.27±2.51) years; there were 44 males and 39 females in the study group, aged (69.50±2.76) years. The control group received butylphthalide treatment, the study group received butylphthalide combined with idebenone treatment, and both groups were treated for 2 months. The carotid peak systolic velocity (PSV), Montreal Cognitive Assessment Scale (MoCA) score, resistance index (RI), Stroke Special Quality of Life Scale (SS-QOL) score, and end diastolic velocity (EDV) before and after treatment and adverse reactions were compared between the two groups. Independent sample t test was used for inter-group comparison of the measurement data, paired t test was used for intra-group comparison of the measurement data, and χ² test was used for the count data.

The MoCA score of the study group after treatment was higher than that of the control group [(23.43±2.75) points vs. (19.79±2.91) points], with a statistically significant difference (P<0.05). Before treatment, there were no statistically significant differences in the carotid hemodynamic indexes between the two groups (all P>0.05); after treatment, the EDV and PSV of the study group were (19.93±4.96) cm/s and (75.95±10.25) cm/s, respectively, higher than those of the control group [(17.55±5.21) cm/s and (70.16±15.16) cm/s], the RI was (0.60±0.07), lower than that of the control group [(0.66±0.17)], with statistically significant differences (all P<0.05). Before treatment, there was no statistically significant difference in the SS-QOL score between the two groups (P>0.05); after treatment, the scores of self-care ability, physical state, psychological state, and life impact of SS-QOL of the study group were (49.35±8.16) points, (52.35±9.44) points, (39.86±6.28) points, and (40.13±5.52) points, respectively, which were higher than those of the control group [(43.55±7.84) points, (46.61±8.93) points, (34.34±6.55) points, and (35.41±6.15) points], with statistically significant differences (all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).

Butylphthalide combined with idebenone can effectively improve the hemodynamic indexes of cerebral artery in elderly patients with vascular dementia, and improve their quality of life and MoCA score.

Vascular dementia; Elderly patients; Butylphthalide; Idebenone; Hemorheology